Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma.
- Author:
Gang CHEN
1
,
2
;
Ding ZHANG
3
;
Yacao YING
3
;
Zhifeng WANG
3
;
Wei TAO
3
;
Hao ZHU
3
;
Jingfeng ZHANG
4
;
Zhiyi PENG
5
Author Information
1. Department of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2. Department of Radiology, Traditional Chinese Medicine Hospital of Ningbo, Ningbo 315010, China.
3. Department of Radiology, Traditional Chinese Medicine Hospital of Ningbo, Ningbo 315010, China.
4. Department of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. jingfengzhang73@163.com.
5. Department of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. pengzhiyi2010@163.com.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular;
diagnostic imaging;
therapy;
Chemoembolization, Therapeutic;
adverse effects;
instrumentation;
methods;
Comparative Effectiveness Research;
Drug Delivery Systems;
instrumentation;
methods;
Epirubicin;
administration & dosage;
therapeutic use;
Humans;
Liver Neoplasms;
Magnetic Resonance Imaging;
Microspheres;
Neoplasm Recurrence, Local;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Zhejiang University. Medical sciences
2017;46(1):44-51
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the efficacy and safety of drug-eluding beads transarterial chemoembolization (DEB-TACE) in treatment of unrecectable hepatocellular carcinoma (HCC).The clinical data of 42 consecutive HCC patients undergoing TACE were retrospectively analyzed, including 20 cases received conventional TACE (cTACE group) and 22 cases received TACE with epirubicine-loaded microspheres (CalliSpheres) (DEB-TACE group). MRI scans were performed 1 week before and 1, 3 and 6 months after initial therapy. The response to treatment, disease recurrence, complications and adverse effects were documented and compared between two groups.There were no significant differences in 1-month, 3-month and 6-month objective response rate (CR+PR) and disease control rate (CR+PR+SD), disease recurrence, complications and adverse effects of interventional therapy between cTACE group and DEB-TACE group. Additionally, there were no significant differences about locoregional biliary injuries, intrahepatic biloma, and newly detected intra- or extrahepatic HCC on MRI between cTACE group and DEB-TACE group.There were no statistically significant differences between cTACE group and DEB-TACE group with regard to the short-term response, disease recurrence, complications and side effects. Hepatic-locoregional complications may be more frequent in DEB-TACE group than those in cTACE group.
